Brief: Telix And Regeneron Announce Radiopharma Collaboration
13/04/2026 02:27
April 13 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX: TELIX PHARMACEUTICALS LTD-TELIX AND REGENERON ANNOUNCE RADIOPHARMA COLLABORATION TO RECEIVE $40 MILLION UPFRONT AND UP TO $2.1 BILLION IN MILESTONES PLUS ROYALTIES Further company coverage: TLX.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)